Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

PURPOSE: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [(166)Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT). The aim of this study was to analyze hematotoxicity profiles, (i.e. lymphocyte and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebbers, Sander C., Brabander, Tessa, Tesselaar, Margot E. T., Hofland, Johannes, Braat, Manon N. G. J. A., Wessels, Frank J., Barentsz, Maarten W., Lam, Marnix G. E. H., Braat, Arthur J. A. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811020/
https://www.ncbi.nlm.nih.gov/pubmed/35107642
http://dx.doi.org/10.1186/s13550-022-00880-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811020/
https://www.ncbi.nlm.nih.gov/pubmed/35107642
http://dx.doi.org/10.1186/s13550-022-00880-4

Ejemplares similares